Lactobacillus plantarum is considered a potential probiotic supplementation for treating
obesity. However, the underlying molecular mechanism is poorly understood. Our previous study displayed that L. plantarum FRT4 alleviated
obesity in mice fed a high-fat diet (HFD) through ameliorating the HFD-induced gut microbiota
dysbiosis. To explore the roles of FRT4 in
obesity prevention, in this study, we investigated changes in serum metabolomic phenotype by ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UHPLC-QTOF/MS) and analyzed the pathway of HFD-fed Kunming female mice orally administered with FRT4 for eight weeks. Using orthogonal partial least squares discriminant analysis (OPLS-DA), metabolite patterns with significant changes were observed. 55 metabolites including
phosphatidylcholine, lysophophatidylcholine,
sphingomyelin,
serotonin, indole-3-methyl aceta,
indole-3-carbinol, indole-5,6-quino, 11,12-DHET,
prostaglandin B2,
leukotriene B4, and
3-hydroxybenzoic acid were identified as potential
biomarkers associated with
obesity, which were mainly involving in
glycerophospholipid metabolism,
tryptophan metabolism, and
arachidonic acid metabolism. Perturbations of 14
biomarkers could be regulated by FRT4 intervention. These metabolites may serve as valuable
biomarkers to understand the mechanisms by which intake of diets containing FRT4 contributes to the treatment or prevention of
obesity. Thus, FRT4 can be a promising dietary supplement for the prevention of HFD-induced
obesity.